JOHNSON & JOHNSON
Add to watch list Add to watch list

Company

profile

overview

growth

risk

operations

valuation

Statements

income

balance sheet

cash flows

Insiders

Buzz Board

  • Compare against:
  • Note: Not all companies will have their earnings statement processed. see following for details. About us

JOHNSON & JOHNSON Earnings Overview

Company overview section gives a snap shot of company and stock performance to quickly determine if the company is worth looking into.

It contains the stock performance overview, and stock volatility expressed in terms of stock turnover ratio (i.e. the average amount of time investors are holding on to their stocks) to give insight into the general mood of investors.

Company perforance is expressed in terms of revenue, net income, cash flows, debt and equity and several risk parameters, to asses the risk/reward profile of the company.

Stock data
Ticker JNJ
Industry Pharmaceutical Preparations
Market value $157,101,960,160
Price per share $57.02
52 week range $57.02 - $66.03
Dividend $3.60
Shares 2,755,208,000
P/E 12.81
EPS $4.45
Stock volatility ( Share turnover )
past week 231 days
past month 249 days
past year 221 days
Earnings ( values in Millions )20092008200720062005200420032002200120001999199819971996199519941993
Revenue$61,897$63,747$61,095$53,324$47,348$41,862$41,862$36,298$32,317$29,846$23,995$22,629$22,629$21,620$18,842$14,138$13,753
Cost of sales$18,447$18,511$17,751$15,057$13,422$12,176$12,176$10,447$9,581$8,908----$7,152$7,018$6,235$4,791$4,678
Gross profit$43,450$45,236$43,344$38,267$33,926$29,686$29,686$25,851$22,736$20,938$23,995$22,629$15,477$14,602$12,607$9,347$9,075
Sales, general and administrative$19,801$21,490$20,451$17,433$15,860$14,131$14,131$12,216$11,260$11,218$9,027$8,715$8,715$8,394$7,462$5,771$5,671
Research and development$6,986$7,758$8,487$7,684$5,221$5,602$5,602$4,146$3,696$3,171$2,634$2,140$2,140$1,905$1,634$1,182$1,127
Restructuring$1,073--$745--------------$8,157$7,152----------
Other expenses----$534--$15----$294$185--$143$129$129$284$166$16$39
Operating income$15,590$15,988$13,127$13,150$12,830$9,953$9,953$9,195$7,595$6,549$4,034$4,493$4,493$4,019$3,345$2,378$2,238
Other income$526$1,015--$671--$385$385----$94--------------
Net interest expense (income)$361$74($156)($766)($8)$30$30($96)($303)($225)($148)($83)($83)($14)$28$46$31
Income before taxes$15,755$16,929$13,283$14,587$12,838$10,308$10,308$9,291$7,898$6,868$4,182$4,576$4,576$4,033$3,317$2,332$2,207
Taxes$3,489$3,980$2,707$3,534$4,329$3,111$3,111$2,694$2,230$1,915$1,179$1,273$1,273$1,146$914$545$582
Income before extraordinary items$12,266$12,949$10,576$11,053$8,509$7,197$7,197$6,597$5,668$4,953$3,003$3,303$3,303$2,887$2,403$1,787$1,625
Cumulative effect of accounting change--------------------------------$595
Net income$12,266$12,949$10,576$11,053$8,509$7,197$7,197$6,597$5,668$4,953$3,003$3,303$3,303$2,887$2,403$1,787$1,030
  • Pharma - The best of
    • Currently 0/5 Stars.
    the best of pharma - Johnson & Johnson valuation compared against, Celgene, Pfizer, Abbott Laboratories, Merck and Bristol Myers Squibb
    by:Ruben Rotteveel 2/19/2010 4:23:51 PM

JOHNSON & JOHNSON Feed